p16(INK4a) immunohistochemical expression is a strong predictor of treatment response and survival in patients with locally advanced squamous cell vulvar cancer undergoing upfront chemoradiotherapy

Journal of Gynecologic Oncology 2026 Open access

Read full text
Authors: Alex Federico, Simona Maria Fragomeni, Valentina Lancellotta, Sara Ammar, Angela Santoro, Alessia Piermattei, Giacomo Corrado, Gabriella Macchia, Luca Tagliaferri, Maria Antonietta Gambacorta, Gian Franco Zannoni, Anna Fagotti
+2 more Giovanni Scambia, Giorgia Garganese
DOI: 10.3802/jgo.2026.37.e137
Cited by: 1
References: 38

Abstract

OBJECTIVE: To evaluate the prognostic significance of tumor p16(INK4a) expression in predicting treatment response and survival in patients with locally advanced squamous cell vulvar cancer (LAVC) undergoing chemoradiotherapy (CRT). METHODS: Retrospective data were collected from patients with stage II-IVB disease managed with definitive or neoadjuvant CRT between January 2016 and March 2024. Clinical response to CRT and survival outcomes according to tumor p16 expression were evaluated. RESULTS: Among 61 patients, 39 (63.9%) had p16-negative (p16-) tumors, 22 (36.1%) had p16-positive (p16+) tumors. p16 positivity was linked to higher complete clinical response (cCR) rates (odds ratio [OR]=9.8; p

Fields of Study & Subjects

Endometrial and Cervical Cancer Treatments Cancer-related Molecular Pathways Colorectal and Anal Carcinomas

Publication details

Journal / source
Journal of Gynecologic Oncology
Publisher
XMLink
Volume
37
Publication date
1 January 2026
Language
EN